FDA Approves Manufacturing Site for C. difficile Preventative Therapy
Recipharm's Vowst therapy is approved to prevent reinfection of C. difficile, which can infect patients with cystic fibrosis and other chronic diseases.
Tag: Recipharm
All
Latest
FDA Approves Manufacturing Site for C. difficile Preventative Therapy
Recipharm’s Vowst therapy is approved to prevent reinfection of C. difficile, which can infect patients with cystic fibrosis and other chronic diseases.
Read More